Antiemetic guidelines: Have we incorporated the changes concerning carboplatin and anthracyclines?

CONCLUSIONS: Use of NEPAd led to a 28% reduction in costs with respect to the use of FOD. A high level of concordance was obtained in both periods between the latest published guideline and healthcare practice in our field. Surveys carried out on patients seem to suggest that both antiemetic therapies have similar effectiveness in clinical practice. The inclusion of NEPAd has led to a reduction in costs, positioning itself as an efficient option.PMID:37268481 | DOI:10.1016/j.farma.2023.04.003

Source: Farmacia Hospitalaria - June 2, 2023 Category: Drugs & Pharmacology Authors: Susana Redondo Capafons Laura Soriano Gutierrez Elsa Dalmau Portulas Àlex Barragán Muñoz Sergio Mart ínez Robles M ònica Gómez-Valent Source Type: research